Biomarkers in Alzheimer's disease drug development.

• Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Nyckelord

Alzheimer Disease

diagnosis

drug therapy

Biological Markers

metabolism

Clinical Trials as Topic

Drug Discovery

Genetic Heterogeneity

Humans

Publikations- och innehållstyp

ref (ämneskategori)

for (ämneskategori)